Kim Ju Young, Kim Hyun Jung
Department of Pediatrics, Eulji University Hospital, Eulji University School of Medicine, 1306, Dunsan-dong, Seo-gu, Daejeon 302-799, Republic of Korea.
Case Rep Cardiol. 2014;2014:821812. doi: 10.1155/2014/821812. Epub 2014 Aug 5.
Kawasaki disease is an acute febrile illness that usually occurs in children younger than 5 years of age. The use of intravenous immunoglobulin (IVIG) within the first 10 days of illness has been shown to reduce the incidence of coronary artery aneurysms significantly. The relative roles of repeated doses of intravenous immunoglobulin (IVIG) are controversial in refractory Kawasaki disease (KD). Most experts recommend the second retreatment with IVIG, 2 g/kg in refractory KD. However, the dose-response effect of the third or fourth IVIG was uncertain. Although there have been a significant number of reports on new therapeutic options for refractory KD, such as steroid, infliximab, methotrexate, and other immunosuppressants, their effectiveness in reducing the prevalence of coronary artery aneurysms was unproven. We present here KD patient with small coronary artery aneurysm who is resistant to the third IVIG and steroid pulse therapy but showed improvement immediately after the infusion of the 4th IVIG on fever day 18.
川崎病是一种急性发热性疾病,通常发生在5岁以下儿童。已证明在发病后10天内使用静脉注射免疫球蛋白(IVIG)可显著降低冠状动脉瘤的发生率。在难治性川崎病(KD)中,重复剂量静脉注射免疫球蛋白(IVIG)的相对作用存在争议。大多数专家建议在难治性KD中第二次使用IVIG进行再治疗,剂量为2 g/kg。然而,第三次或第四次IVIG的剂量反应效果尚不确定。尽管有大量关于难治性KD新治疗选择的报道,如类固醇、英夫利昔单抗、甲氨蝶呤和其他免疫抑制剂,但它们在降低冠状动脉瘤患病率方面的有效性尚未得到证实。我们在此报告一例患有小冠状动脉瘤的KD患者,该患者对第三次IVIG和类固醇脉冲疗法耐药,但在发热第18天输注第四次IVIG后立即出现改善。